natgillin/translations-raw huggingface dataset:
The binding protein of any one of claims 1 to 5, wherein the polyethylene glycol moiety has a molecular weight of about 10 kDa to about 40 kDa. 
Vezivni protein sukladno bilo kojem od patentnih zahtjeva 1 do 5, naznačen time što polietilenglikolni ostatak ima molekulsku masu od oko 10 kDa do oko 40 kDa.
A pharmaceutical composition comprising the binding protein of any one of claims 1 to 7 and optionally a pharmaceutically acceptable carrier and/or diluent. 
Farmaceutski pripravak koji sadrži vezivni protein sukladno bilo kojem od patentnih zahtjeva 1 do 7 i izborno farmaceutski prihvatljiv nosač i/ili otapalo.
A pharmaceutical composition according to claim 8 for use in the treatment of an eye disease. 
Farmaceutski pripravak sukladno patentnom zahtjevu 8, radi liječenja bolesti oka.
A pharmaceutical composition according to claim 8 for use in the treatment of an eye disease by intravitreal injection. 
Farmaceutski preparat prema patentnom zahtjevu 8, radi liječenja bolesti oka intravitrealnom injekcijom.
A pharmaceutical composition according to claim 8 for use in the treatment of a retinal ischemic disease. 
Farmaceutski pripravak sukladno patentnom zahtjevu 8, radi liječenja retinalne ishemične bolesti.
A pharmaceutical composition for use according to claim 9 wherein the eye disease is wet macular degeneration. 
Farmaceutski pripravak sukladno patentnom zahtjevu 9, naznačen time da je očna bolest vlažna makularna degeneracija.
A pharmaceutical composition for use according to claim 9 wherein the eye disease is diabetic macular edema. 
Farmaceutski pripravak sukladno patentnom zahtjevu 9, naznačen time da je očna bolest dijabetički makularni edem.
An evertable catheter tube (10) comprising 
Reverzibilna kateterska cijev (10) koja sadrži
The evertable catheter tube (10) according to any one of the preceding claims, wherein the evertable catheter tube (10) further comprises at least one of the additional components, the additional components being 
Reverzibilna kateterska cijev (10) prema bilo kojem od prethodnih zahtjeva, pri čemu reverzibilna kateterska cijev (10) nadalje sadrži najmanje jednu od dodatnih komponenti, koje dodatne komponente su
a connector (9), the connector (9) being disposed at the second end (12) of the evertable catheter tube (10). 
konektor (9), pri čemu je konektor (9) postavljen na drugom kraju (12) reverzibilne kateterske cijevi (10).
manufacturing an evertable catheter tube (10) with longitudinal protrusions (14) facing radially outwards, and 
izradu reverzibilne kateterske cijevi (10) sa uzdužnim izbočenjima (14) radijalno usmjerenim prema van, i
A method of manufacture of the evertable catheter tube (10) of claim 1 comprising the step of manufacturing the evertable catheter tube (10) with longitudinal protrusions (14) facing radially inwards by extrusion, injection molding or 3D print. 
Postupak izrade reverzibilne kateterske cijevi (10) prema zahtjevu 1, obuhvaćajući korak izrade reverzibilne kateterske cijevi (10) sa uzdužnim izbočenjima (14) usmjerenim radijalno prema unutra, putem ekstruzije, injekcijskog lijevanja ili 3D tiskanja.
The method of manufacture of the evertable catheter tube (10) according to claim 11 to 14, the method further comprising at least one of the following subsequent steps: 
Postupak izrade reverzibilne kateterske cijevi (10) prema zahtjevu 11 do 14, koji postupak nadalje obuhvaća barem jedan od sljedećih naknadnih koraka:
everting a first end (11) of the evertable catheter tube (10) inside out, creating an everted region (6) of the evertable catheter tube (10), 
presavijanje prvog kraja (11) reverzibilne kateterske cijevi (10) iznutra prema van, tvoreći presavijeno područje (6) reverzibilne kateterske cijevi (10),
attaching a guard (7) to the everted region (6) of the evertable catheter tube (10), 
pričvršćivanje štitnika (7) na presavijeno područje (6) reverzibilne kateterske cijevi (10),
attaching a gripper (8) to the evertable catheter tube (10), and 
pričvršćivanje hvataljke (8) na reverzibilnu katetersku cijev (10), i
attaching a connector (9) 8 to the second end (12) of the evertable catheter tube (10). 
pričvršćivanje konektora (9) na drugi kraj (12) reverzibilne kateterske cijevi (10).
A WC according to claim 1, characterised in that said opening (6) has a flow-through section with an area ranging from 30 to 40% of the area of the flow-through section of the outlet portion (9). 
WC u skladu s patentnim zahtjevom 1, naznačen time, da navedeni otvor (6) ima presjek protoka površine u rasponu od 30 do 40 % površine prolaznog dijela izlaznog dijela (9).
A method for preparing a solid composition comprising an organic acid, the method comprising a step of dispersing the organic acid in molten xylitol such as to form a mixture, and subsequently allowing the mixture to solidify, wherein the organic acid is provided in powder form. 
Postupak pripreme čvrstog sastava koji sadrži organsku kiselinu, postupak obuhvaćajući korak disperzije organske kiseline u otopljenom ksilitolu kako bi se postigla mješavina, i naknadno puštanje mješavine da očvrsne, pri čemu je organska kiselina predviđena u obliku praha.
The method of claim 1, wherein the organic acid is selected from citric acid, fumaric acid, tartaric acid, malic acid, succinic acid and ascorbic acid. 
Postupak iz zahtjeva 1, pri čemu je organska kiselina odabrana od limunske kiseline, fumarne kiseline, vinske kiseline, jabučne kiseline, jantarne kiseline i askorbinske kiseline.
The method of claim 2, wherein the organic acid is fumaric acid. 
Postupak iz zahtjeva 2, pri čemu je organska kiselina fumarna kiselina.
dispersing the fumaric acid in the molten xylitol such as to form a mixture, followed by 
otapanja ksilitola, disperzije fumarne kiseline u otopljenom ksilitolu kako bi se postigle mješavina, nakon koje slijedi
cooling the mixture to a temperature below about 94°C, followed by 
hlađenje mješavine na temperaturu ispod otprilike 94 °C, nakon kojeg slijedi
adding crystalline xylitol to the mixture before the mixture has solidified, followed by 
dodavanje kristalnog ksilitola mješavini prije nego je mješavina očvrsnula, nakon kojeg slijedi
allowing the mixture to solidify. 
puštanje mješavine da očvrsne.
The method of claim 4, wherein the crystalline xylitol is added in step c) after the mixture is cooled to about 88-92 °C, and/or while the mixture is still liquid. 
Postupak iz zahtjeva 4, pri čemu je kristalan ksilitol dodan u koraku c) nakon što je mješavina ohlađena na otprilike 88 – 92 °C, i/ili dok je mješavina još u tekućem obliku.
The method of any preceding claim, wherein the melt-processing temperature is at least 91 °C and less than 180 °C, preferably at least 91 °C but not higher than 120 °C. 
Postupak iz bilo kojeg od prethodnih zahtjeva, pri čemu je temperatura prerade taline barem 91 °C i manja od 180 °C, poželjno barem 91 °C no ne viša od 120 °C.
A solid composition obtainable by the method of any one of claims 1 to 6. 
Čvrsti sastav koji se može dobiti putem postupka iz bilo kojeg od zahtjeva 1 do 6.
The solid dispersion of claim 8, wherein the organic acid is fumaric acid. 
Čvrsta disperzija iz zahtjeva 8, pri čemu je organska kiselina fumarna kiselina.
A solid pharmaceutical composition comprising: 
Čvrsti farmaceutski sastav obuhvaćajući:
the solid composition of claim 7 or the solid dispersion of claims 8 to 10. 
čvrsti sastav iz zahtjeva 7 ili čvrsta disperzija iz zahtjeva 8 do 10.
The solid pharmaceutical composition of claim 11, wherein the calcium salt is selected from calcium acetate, calcium carbonate, calcium chloride or a combination thereof. 
Čvrsti farmaceutski sastav iz zahtjeva 11, pri čemu je kalcijeva sol odabrana od kalcijeva acetata, kalcijeva karbonata, kalcijeva klorida ili kombinacije istih.
The solid pharmaceutical composition of claim 12, wherein the calcium salt is calcium acetate and/or the magnesium salt is magnesium carbonate. 
Čvrsti farmaceutski sastav iz zahtjeva 12, pri čemu je kalcijeva sol kalcijev acetat i/ili magnezijeva sol je magnezijev karbonat.
The solid pharmaceutical composition of claims 10 to 13, being in the form of granules, direct-to-mouth granules, a powder for oral use, a tablet, a chewable tablet, or an orally disintegrating tablet. 
Čvrsti farmaceutski sastav iz zahtjeva 10 do 13, bivajući u obliku granula, raspadljivih granula, praška za oralnu primjenu, tablete, tablete za žvakanje, ili tablete koja se razgrađuje u usnoj šupljini.
The solid pharmaceutical composition of claims 10 to 14 for use in the treatment or the prevention of hyperphosphatemia associated with chronic renal insufficiency in patients undergoing hemodialysis or peritoneal dialysis (CKD stage 5) or in patients with CKD stage 4 or earlier. 
Čvrsti farmaceutski sastav iz zahtjeva 10 do 14 za korištenje u tretmanu ili prevenciji hiperfosfatemije povezane s kroničnom bubrežnom insuficijencijom kod pacijenata koji prolaze kroz hemodijalizu ili peritonealnu dijalizu (CKD stadij 5) ili kod pacijenata s CKD stadijem 4 ili ranije.
wherein said liposomes contain substantially no internal cryoprotectant, and wherein, when said gel-phase liposomal composition is reconstituted in a pharmaceutical carrier, the mean diameter of the liposomes is maintained whereby said mean diameter does not increase more than 50% on a volume weighted basis as compared to said composition prior to lyophilization, and said agents are retained in the liposomes. 
gdje spomenuti liposomi bitno ne sadrže unutarnji krioprotektor, i gdje, kad spomenuti sastav liposoma u obliku gela je rekonstruiran u farmaceutskom nosaču, srednja vrijednost promjera liposoma je održavana dok se spomenuti srednji promjer ne povećava više od 50% na osnovi izmjerenog volumena u odnosu na sastav prije liofilizacije i spomenuta sredstva su zadržana u liposomima.
The composition of claim 1 wherein said liposome membrane is composed of distearoylphosphatidylcholine (DSPC), distearoylphosphatidylglycerol (DSPG) and cholesterol (CHOL). 
Sastav prema zahtjevu 1, gdje je spomenuta liposomska membrana sastavljena od distearoilfosfatidilkolina (DSPC), distearoilfosfatidilglicerola (DSPG) i kolesterola (CHOL).
The composition of claim 6, wherein the liposome membrane is composed of 50-80 mol% DSPC, 1-20 mol% DSPG and 1-20 mol% CHOL. 
Sastav prema zahtjevu 2, gdje je liposomska membrana sastavljena od 50-80 mol% DSPC, 1-20 mol% DSPG i 1-20 mol% CHOL.
The composition of claim 2 wherein the liposome membrane is composed of DSPC, DSPG and CHOL in a 7:2:1 molar ratio and the liposomes contain no internal cryoprotectant. 
Sastav prema zahtjevu 2, gdje je liposomska membrana sastavljena od DSPC, DSPG i CHOL u molarnom omjeru 7:2:1 i liposomi ne sadrže unutarnji krioprotektor.
The composition of any one of claims 1-4 wherein the agents are antineoplastic agents. 
Sastav prema bilo kojem od zahtjeva 1-4, gdje su sredstva antineoplastična sredstva.
The composition of claim 2 wherein the liposome membrane is composed of DSPC, DSPG and CHOL in a 7:2:1 molar ratio and wherein (i) the antineoplastic agents daunorubicin and cytarabine are encapsulated in said liposomes at a 1:5 molar ratio; or (ii) the antineoplastic agents irinotecan and floxuridine are encapsulated in said liposomes at a 1:1 molar ratio. 
Sastav prema zahtjevu 2, gdje je liposomska membrana sastavljena od DSPC, DSPG i CHOL u molarnom omjeru 7:2:1 i gdje (i) antineoplastična sredstva daunorubicin i citarabin su kapsulirana u spomenute liposome u molarnom omjeru 1:5; ili (ii) antineoplastična sredstva irinotekan i floksuridin su kapsulirana u spomenute liposome u molarnom omjeru 1:1.
The composition of claim 1, wherein agents encapsulated in said liposomes are at a fixed ratio and wherein, when said composition is reconstituted, said ratio of the agents changes by no more than 25% as compared to said composition prior to lyophilization. 
Sastav prema zahtjevu 1, gdje sredstva kapsulirana u spomenute liposome su u određenom odnosu i gdje, kad je spomenuti sastav rekonstituiran, spomenuti odnos sredstava se mijenja, ali ne više od 25% u odnosu na spomenuti sastav prije liofilizacije.
The composition of any one of claims 1-4, wherein at least 75% of each agent is retained upon reconstitution of said liposomes. 
Sastav prema bilo kojem od zahtjeva 1-4, gdje bar 75% svakog sredstva je zadržano poslije rekonstrukcije spomenutih liposoma.
The composition of any one of claims 1-4, wherein the size distribution of the liposomes changes by no more than 25% after lyophilization and upon reconstitution of said liposomes. 
Sastav prema bilo kojem od zahtjeva 1-4, gdje raspored veličine liposoma se mijenja, ali ne više od 25% poslije liofilizacije i poslije rekonstrukcije spomenutih liposoma.
The method of claim 13 wherein said aqueous medium comprising said gel-phase liposomes is frozen at a temperature which is below the glass transition temperature (Tg) of said medium. 
Postupak prema zahtjevu 13, gdje je spomenuti vodeni medij koji sadrži spomenute liposome u obliku gela, zamrznut na temperaturi koja je ispod temperature prelaska u staklo (Tg) spomenutog medija.
A method to prepare a pharmaceutical composition for administering therapeutic and/or diagnostic agents to a subject, which method comprises reconstituting the liposomal composition of any one of claims 1-4 in a pharmaceutical carrier to obtain a reconstituted composition. 
Postupak za pripremanje farmaceutskog sastava za davanje terapeutskog i/ili dijagnostičkog sredstva subjektu, koji obuhvaća rekonstruiranje liposomnog sastava prema bilo kojem od zahtjeva 1-4 u farmaceutskom nosaču da bi se dobio rekonstruirani sastav.
The reconstituted composition of claim 15 for use as a medicament. 
Rekonstruirani sastav prema zahtjevu 15 za uporabu kao lijek.
A compound according to claim 1 wherein Hal is Cl. 
Spoj prema patentnom zahtjevu 1 pri čemu je Hal Cl.
A pharmaceutical composition comprising a compound of formula (II): wherein: 
Farmaceutski pripravak koji sadrži spoju formule (II):
A compound of general formula (I), or a stereoisomer, pharmaceutically acceptable salt or hydrate thereof, wherein, 
Spoj opće formule (I), ili stereoizomer, farmaceutski prihvatljiva sol ili hidrat istog, pri čemu
Y is CO; Z is a covalent bond; n is an integer from 1 to 4; and 
Y je CO; Z je kovalentna veza; n je cijeli broj od 1 do 4; i Prsten A je benzenski prsten.
A method for preparing the compound of general formula (I) according to claim 1, comprising reacting a compound of general formula (IV) with a compound of general formula (V) under organic solvent and a catalyst to form the compound of general formula (I), wherein 
Postupak proizvodnje spoja opće formule (I) prema zahtjevu 1, obuhvaćajući reakciju spoja opće formule (IV) sa spojem opće formule (V) pod organskim otapalom i katalizatorom za formiranje spoja opće formule (I), pri čemu
A pharmaceutical composition for use in the treatment of diseases related to abnormal activities of JAK3 and/or JAK1 kinases, comprising the compound of general formula (I) according to claim 1 as the active ingredient and a pharmaceutically acceptable carrier, adjuvant or diluent. 
Farmaceutski sastav za korištenje u liječenju bolesti povezanih s abnormalnim aktivnostima JAK3 i/ili JAK1 kinaza, obuhvaćajući spoj opće formule (I) prema zahtjevu 1 kao aktivan sastojak i farmaceutski prihvatljiv nosač, pomoćno sredstvo ili razrjeđivač.
Use of the compound according to any one of claims 1 to 8 in the preparation of a medicament for the treatment or prevention of autoimmune diseases, inflammatory diseases, cancers, myeloproliferative diseases, bone resorption diseases, graft-versus-host diseases, rheumatoid arthritis, psoriasis, Crohn's disease, systemic lupus erythematosus, multiple sclerosis, type I diabetes, allergic diseases, chronic obstructive pulmonary disease, asthma, leukaemia, and lymphoma. 
Korištenje spoja prema bilo kojem od zahtjeva 1 do 8 u pripremi lijeka za liječenje ili prevenciju autoimunih bolesti, upalnih bolesti, rakova, mijeloproliferativnih bolesti, bolesti resorpcije kosti, bolesti presatka protiv primatelja, reumatoidnog artritisa, psorijaze, Crohnove bolesti, sistemskog eritemskog lupusa, multiple skleroze, tip I dijabetesa, alergijskih bolesti, kronične opstruktivne plućne bolesti, astme, leukemije i limfoma.
Use of the pharmaceutical composition according to claim 11 in the preparation of a medicament for the treatment or prevention of autoimmune diseases, inflammatory diseases, cancers, myeloproliferative diseases, bone resorption diseases, graft-versus-host diseases, rheumatoid arthritis, psoriasis, Crohn's disease, systemic lupus erythematosus, multiple sclerosis, type I diabetes, allergic diseases, chronic obstructive pulmonary disease, asthma, leukaemia, and lymphoma. 
Korištenje farmaceutskog sastava prema zahtjevu 11 u pripremi lijeka za liječenje ili prevenciju autoimunih bolesti, upalnih bolesti, rakova, mijeloproliferativnih bolesti, bolesti resorpcije kosti, bolesti presatka protiv primatelja, reumatoidnog artritisa, psorijaze, Crohnove bolesti, sistemskog eritemskog lupusa, multiple skleroze, tip I dijabetesa, alergijskih bolesti, kronične opstruktivne plućne bolesti, astme, leukemije i limfoma.
A footlet (1) according to claim 1 or 2, characterised in that the anti-slip element (41, 51, 61) comprises silicones. 
Stopica (1) u skladu s patentnim zahtjevom 1 ili 2, naznačena time što element protiv proklizavanja (41, 51, 61) sadrži silikone.
A footlet (1) according to any one of the preceding claims 1 - 3, characterised in that the anti-slip element (51, 61) comprises a number of spaced-apart anti-slip parts (52, 62). 
Stopica (1) u skladu s bilo kojim od prethodnih patentnih zahtjeva 1-3, naznačena time što element protiv proklizavanja (51, 61) sadrži više međusobno razmaknutih dijelova protiv proklizavanja (52, 62).
A footlet (1) according to claim 6 or 7, characterised in that the anti-slip parts (52, 62) are block-shaped or strip-shaped. 
Stopica (1) u skladu s patentnim zahtjevom 6 ili 7, naznačena time što su dijelovi protiv proklizavanja (52, 62) u obliku bloka ili u obliku pruge.
A footlet (1) according to any one of the preceding claims, characterised in that the anti-slip element (41, 51, 61) extends along a length of 2 - 7 cm over the elastic band (16, 26, 36). 
Stopica (1) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što se element protiv proklizavanja (41, 51, 61) pruža po duljini od 2-7 cm preko elastične vrpce (16, 26, 36).
A footlet (1) according to claim 1, characterised in that the anti-slip element (41, 51, 61) extends over the elastic band (16, 26, 36) over a width of 2 - 6 mm transversely to the length. 
Stopica (1) u skladu s patentnim zahtjevom 1, naznačena time što se element protiv proklizavanja (41, 51, 61) pruža preko elastične vrpce (16, 26, 36) po širini od 2-6 mm poprečno u odnosu na duljinu.
A footlet (1) according to any one of the preceding claims, characterised in that the footlet (1) is entirely made by reciprocating knitting and that subsequently the anti-slip element (41, 51, 61) is applied to the elastic band (16, 26, 36). 
Stopica (1) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je stopica (1) u potpunosti načinjena naizmjeničnim pletenjem, te što se naknadno primjenjuje element protiv proklizavanja (41, 51, 61) na elastičnu vrpcu (16, 26, 36).
A method according to claim 12, characterised in that the anti-slip element (41, 51, 61) is applied to the elastic band (16, 26, 36) by means of screen-printing, template printing, heat transfer or by means of a dispenser. 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što se element protiv proklizavanja (41, 51, 61) primjenjuje na elastičnu vrpcu (16, 26, 36) sitotiskom, šablonskim tiskom, prijenosom topline ili dozirkom.
A method according to claim 12 or 13, characterised in that a stretching force is applied the elastic band (16, 26, 36) prior to the application of the anti-slip element (41, 51, 61), as a result of which the elastic band (16, 26, 36) is stretched from a starting length to a length 1.5 - 3 times greater than the starting length, and that subsequently the anti-slip element (41, 51, 61) is applied, after which the stretching force is released. 
Postupak u skladu s patentnim zahtjevom 12 ili 13, naznačen time što se silu rastezanja primjenjuje na elastičnu vrpcu (16, 26, 36) prije primjene elementa protiv proklizavanja (41, 51, 61), zbog čega se elastična vrpca (16, 26, 36) rastegne od početne duljine do duljine 1,5-3 puta veće od početne duljine, te što se naknadno primjenjuje element protiv proklizavanja (41, 51, 61), nakon čega se otpušta silu rastezanja.
A method of preparing omecamtiv mecarbil dihydrochloride hydrate salt comprising admixing methyl 4-(3-amino-2-fluorobenzyl)piperazine-1-carboxylate and phenyl (6-methylpyridin-3-yl)carbamate in the presence of a trialkylamine base to form omecamtiv mecarbil; and further comprising crystallizing the omecamtiv mecarbil in the presence of aqueous hydrochloric acid and an alcohol solvent to form the omecamtiv mecarbil dihydrochloride hydrate salt, for example, wherein the alcohol solvent comprises isopropyl alcohol. 
Postupak za pripravu dihidroklorid hidratne soli omekamtiv mekarbila naznačen time što sadrži miješanje metil 4-(3-amino-2-fluorobenzil)piperazin-1-karboksilata i fenil (6-metilpiridin-3-il)karbamata u prisutnosti trialkilamin baze kako bi nastao omekamtiv mekarbil; i nadalje sadrži kristaliziranje omekamtiv mekarbila u prisutnosti vodene klorovodične kiseline i alkoholnog otapala kako bi nastala dihidroklorid hidratna sol omekamtiv mekarbila, na primjer, pri čemu alkoholno otapalo sadrži izopropilni alkohol.
The method of claim 9, wherein the omecamtiv mecarbil dihydrochloride hydrate salt has an x-ray powder diffraction pattern (XRPD) comprising peaks at 6.6, 14.9, 20.1, 21.4, and 26.8 ± 0.2° 2θ using Cu Ka radiation, optionally wherein the x-ray powder diffraction pattern further comprises peaks at 8.4, 24.2, 26.0, and 33.3 ± 0.2° 2θ using Cu Ka radiation, and/or optionally wherein the x-ray powder diffraction pattern further comprises peaks at 6.2, 9.7, 13.2, 14.3, 15.4, 16.3, 16.9, 18.9, 19.5, 20.7, 21.8, 22.8, 23.6, 25.1, 27.3, 27.7, 28.4, 29.4, 30.2, 31.2, 31.5, 31.9, 33.9, 34.5, 34.9, 36.1, 36.8, 37.7, 38.5, and 39.7 ± 0.2° 2θ using Cu Ka radiation. A method according to claim 9, comprising: 
Postupak prema zahtjevu 9, naznačen time što dihidroklorid hidratna sol omekamtiv mekarbila ima uzorak rendgenske difrakcije na prahu (XRPD) koji sadrži vrhove kod 6.6, 14.9, 20.1, 21.4, i 26.8 ± 0.2° 2θ korištenjem Cu Ka zračenja, proizvoljno pri čemu uzorak rendgenske difrakcije na prahu nadalje sadrži vrhove kod 8.4, 24.2, 26.0, i 33.3 ± 0.2° 2θ korištenjem Cu Ka zračenja, i/ili proizvoljno pri čemu uzorak rendgenske difrakcije na prahu nadalje sadrži vrhove kod 6.2, 9.7, 13.2, 14.3, 15.4, 16.3, 16.9, 18.9, 19.5, 20.7, 21.8, 22.8, 23.6, 25.1, 27.3, 27.7, 28.4, 29.4, 30.2, 31.2, 31.5, 31.9, 33.9, 34.5, 34.9, 36.1, 36.8, 37.7, 38.5, i 39.7 ± 0.2° 2θ korištenjem Cu Ka zračenja.
crystallizing the omecamtiv mecarbil free base in the presence of aqueous hydrochloric acid and an alcohol solvent to form omecamtiv mecarbil dihydrochloride hydrate salt. 
kristaliziranje slobodne baze omekamtiv mekarbila u prisutnosti vodene klorovodične kiseline i alkoholnog otapala kako bi nastala dihidroklorid hidratna sol omekamtiv mekarbila.